NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5144
-0.0256 (-4.74%)
At close: 4:00PM EST

0.5150 -0.01 (-1.59%)
After hours: 4:42PM EST

Stock chart is not supported by your current browser
Previous Close0.5400
Open0.5400
Bid0.5177 x 1100
Ask0.5600 x 1300
Day's Range0.5144 - 0.5400
52 Week Range0.4000 - 5.2100
Volume35,539
Avg. Volume83,260
Market Cap6.67M
Beta (3Y Monthly)4.24
PE Ratio (TTM)N/A
EPS (TTM)-1.5080
Earnings DateNov 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.83
  • Business Wire

    Novus Therapeutics to Participate in Two Investor Conferences

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate in two investor conferences in December. Novus Therapeutics, Inc. (Novus) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT).

  • Business Wire

    Novus Therapeutics Reports Third Quarter 2019 Financial Results

    -- Management to participate in two investor conferences in December 2019 --

  • Business Wire

    Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the U.S. Food and Drug Administration (FDA) has agreed with the Company’s proposed patient population, endpoints, and statistical analysis plan for a phase 2a study of OP0201 in patients with chronic otitis media with effusion (COME) (study C-009). The FDA’s feedback on the study C-009 was detailed in the minutes from a Type C meeting held with the Company’s management team on September 20, 2019. Study C-009 is designed to explore the effect of daily administration of OP0201 in patients with COME, a non-infectious form of otitis media.

  • Do Institutions Own Shares In Novus Therapeutics, Inc. (NASDAQ:NVUS)?
    Simply Wall St.

    Do Institutions Own Shares In Novus Therapeutics, Inc. (NASDAQ:NVUS)?

    If you want to know who really controls Novus Therapeutics, Inc. (NASDAQ:NVUS), then you'll have to look at the makeup...

  • GlobeNewswire

    Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market

    Adynxx, Inc. (ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases, today announced that Gregory J. Flesher, Chief Executive Officer at Novus Therapeutics Inc. (NVUS), has been appointed to the Adynxx Board of Directors. In addition, Adynxx also announced today that it satisfied the requirements for listing of the Company’s shares on the OTCQB Market (OTCQB) and will begin trading on the OTCQB today.

  • Investors Who Bought Novus Therapeutics (NASDAQ:NVUS) Shares A Year Ago Are Now Down 86%
    Simply Wall St.

    Investors Who Bought Novus Therapeutics (NASDAQ:NVUS) Shares A Year Ago Are Now Down 86%

    It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try...

  • Business Wire

    Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that data from OP0201 study C-002 will be presented during the 20th International Symposium on Recent Advances in Otitis Media, being held June 9-13, 2019 in Los Angeles, CA. Study C-002 was a phase 1 randomized, double-blind, placebo-controlled, parallel-group, dose-escalation clinical trial designed to evaluate safety and tolerability of 14 days of daily intranasal OP0201 (30 mg per day or 60 mg per day) compared to placebo in 30 healthy adults. The study was conducted at a single phase 1 unit in the United States.

  • Business Wire

    Novus Therapeutics Reports First Quarter 2019 Financial Results

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter ended March 31, 2019.

  • Business Wire

    Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the closing of its previously announced registered direct offering of 3,449,112 shares of its common stock, at a purchase price per share of $3.095, priced at-the-market, to healthcare-focused institutional investors, led by OrbiMed, BVF Partners L.P., and Armistice Capital. Novus also issued unregistered warrants to purchase up to 6,898,224 shares of common stock. The warrants were issued in two tranches.

  • Business Wire

    Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 3,449,112 shares of its common stock, at a purchase price per share of $3.095, in a registered direct offering priced at-the-market. Additionally, Novus has also agreed to issue to the investors unregistered warrants to purchase up to 6,898,224 shares of common stock. The warrants are being issued in two tranches.

  • Business Wire

    Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials

    The primary objective of establishing safety and tolerability was achieved in both healthy adults (study C-001) and in adults with acute otitis media (study C-004). “We are delighted that results from single-dose phase 1 studies met the primary objectives and demonstrated a favorable safety and tolerability profile,” said Dr. Catherine Turkel, President of Novus Therapeutics, “The safety profile of OP0201 was similar to placebo, and also similar when administered to healthy adults or adults with acute otitis media.

  • Business Wire

    Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter and year ended December 31, 2018 and provided updates on the OP0201 development program.

  • Business Wire

    Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will participate at the 8th Annual SVB Leerink Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace, New York. Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”).

  • Business Wire

    Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first patients in a phase 2a trial of OP0201, the company’s lead product candidate being developed for otitis media. “We are pleased to be working with Dr. Alejandro Hoberman and the clinical research staff at the University of Pittsburgh on study C-006,” said Dr. Catherine Turkel, President of Novus Therapeutics. “Acute otitis media affects millions of people every year, particularly young children who account for more than half of the incident cases annually.

  • Business Wire

    Company Profile for Novus Therapeutics, Inc.

    Novus Therapeutics, Inc. is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat . Novus has two technologies, each that has the potential to be developed for multiple ENT indications.

  • Business Wire

    Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult subjects in study C-001, a phase 1 pharmacodynamics clinical trial of OP0201, the company’s lead product candidate being developed for otitis media. Dr. Catherine Turkel, President of Novus Therapeutics, stated, “In addition to collecting additional safety information, this study aims to explore the potential effect of OP0201 on Eustachian tube function as subjects are exposed to changes in atmospheric pressure.

  • Business Wire

    Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials

    Screening Initiated for Phase 1 Pharmacodynamic Effects Trial

  • Business Wire

    Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult patient with acute otitis media in a phase 1 clinical trial of OP0201, the company’s lead product candidate being developed for otitis media. “This phase 1 study will provide additional safety information in adults with acute otitis media and will help us better understand the onset of symptom relief following an initial dose of OP0201,” said Dr. Catherine Turkel, President of Novus Therapeutics. Study OP0201-C-004 (“C-004”) is a phase 1 clinical trial designed to evaluate safety and relief of ear pain following a single intranasal dose of OP0201 over a 60-minute observation period in 24 adults with acute otitis media.

  • Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?
    Simply Wall St.

    Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?

    The big shareholder groups in Novus Therapeutics, Inc. (NASDAQ:NVUS) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own Read More...